These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 31371939

  • 1. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [Abstract] [Full Text] [Related]

  • 2. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
    Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD.
    Respir Res; 2019 Nov 04; 20(1):242. PubMed ID: 31684965
    [Abstract] [Full Text] [Related]

  • 3. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 04; 13():3971-3981. PubMed ID: 30587953
    [Abstract] [Full Text] [Related]

  • 4. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 04; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 5. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 6. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
    Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T.
    Cochrane Database Syst Rev; 2017 Feb 10; 2(2):CD012066. PubMed ID: 28185242
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 10; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 8. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH, Tan DJ, Walters JA, Walters EH.
    Cochrane Database Syst Rev; 2023 Dec 06; 12(12):CD011600. PubMed ID: 38054551
    [Abstract] [Full Text] [Related]

  • 9. Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.
    Petite SE.
    Ann Pharmacother; 2017 Aug 06; 51(8):696-705. PubMed ID: 28410560
    [Abstract] [Full Text] [Related]

  • 10. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y, Keeney E, Ghatehorde N, Dias S.
    Cochrane Database Syst Rev; 2018 Dec 03; 12(12):CD012620. PubMed ID: 30521694
    [Abstract] [Full Text] [Related]

  • 11. Current appraisal of single inhaler triple therapy in COPD.
    Lipworth B, Kuo CR, Jabbal S.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 03; 13():3003-3009. PubMed ID: 30319248
    [Abstract] [Full Text] [Related]

  • 12. Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.
    Zayed Y, Barbarawi M, Kheiri B, Haykal T, Chahine A, Rashdan L, Hamid K, Sundus S, Banifadel M, Aburahma A, Bachuwa G, Chandran A.
    Clin Respir J; 2019 Jul 03; 13(7):413-428. PubMed ID: 30947394
    [Abstract] [Full Text] [Related]

  • 13. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr 03; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr 03; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 15. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
    Tariq SM, Thomas EC.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr 03; 12():1877-1882. PubMed ID: 28694698
    [Abstract] [Full Text] [Related]

  • 16. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
    Bloom CI, Elkin SL, Quint JK.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr 03; 14():279-287. PubMed ID: 30774325
    [Abstract] [Full Text] [Related]

  • 17. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr 03; 12():2917-2928. PubMed ID: 29062229
    [Abstract] [Full Text] [Related]

  • 18. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
    Lee HW, Kim HJ, Jang EJ, Lee CH.
    Respiration; 2021 Apr 03; 100(7):631-643. PubMed ID: 33971649
    [Abstract] [Full Text] [Related]

  • 19. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.
    Long H, Xu H, Janssens JP, Guo Y.
    Respir Res; 2021 Jul 23; 22(1):209. PubMed ID: 34301267
    [Abstract] [Full Text] [Related]

  • 20. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A, Jankowski M, Gross-Sondej I, Storman M, Nowobilski R, Bala MM.
    Cochrane Database Syst Rev; 2018 Aug 24; 8(8):CD012355. PubMed ID: 30141826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.